Table 1 The distribution of the training set and testing set of 164 patients
Data set (year) | Number (%) | WHO pathological subtypes | Traditional risk grouping | Improved risk grouping | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type A | Type AB | Type B1 | Type B2 | Type B3 | TC | LRT | HRT | TC | LRT* | HRT* | TC | ||
(A/AB/B1) | (B2/B3) | (A/AB) | (B1/B2/B3) | ||||||||||
All data | 164 | 15 | 19 | 26 | 34 | 24 | 46 | 60 | 58 | 46 | 34 | 84 | 46 |
(2012–2021) | (100%) | (9.1%) | (11.6%) | (15.9%) | (20.7%) | (14.6%) | (28.0%) | (36.6%) | (35.4%) | (28.0%) | (20.7%) | (51.2%) | (28.0%) |
Traini ng set | 130 | 13 | 14 | 21 | 26 | 20 | 36 | 48 | 46 | 36 | 27 | 67 | 36 |
(2012–2018) | (79%) | (10.0%) | (10.8%) | (16.2%) | (20.0%) | (15.4%) | (27.7%) | (36.9%) | (35.4%) | (27.7%) | (20.8%) | (51.5%) | (27.7%) |
Testing set | 34 | 2 | 5 | 5 | 8 | 4 | 10 | 12 | 12 | 10 | 7 | 17 | 10 |
(2019–2021) | (21%) | (6.9%) | (14.7%) | (14.7%) | (23.5%) | (11.8%) | (29.4%) | (35.3%) | (35.3%) | (29.4%) | (20.6%) | (50.0%) | (29.4%) |